Peripheral artery disease and atrial fibrillation: A potentially dangerous combination

Internal and Emergency Medicine

Volumn 7, Issue 3, 2012, Pages 213-218

  Violi, Francesco ^a   Lip, Gregory Y H ^b   Basili, Stefania ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Atrial fibrillation; Peripheral artery disease

Indexed keywords

FIBRINOLYTIC AGENT;

ARTERIOSCLEROSIS; HEART ATRIUM FIBRILLATION; HUMAN; PATHOLOGY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; REVIEW; RISK FACTOR; UNITED STATES;

ARTERIOSCLEROSIS; ATRIAL FIBRILLATION; FIBRINOLYTIC AGENTS; HUMANS; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; UNITED STATES;

EID: 84862173378     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0637-0     Document Type: Review

References (46)

1. Hughes M, Lip GY (2008) Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 99: 295-304.
2. Watson T, Shantsila E, Lip GY (2009) Mechanisms of thrombogenesis in atrial fibrillation: Virchow's triad revisited. Lancet 373: 155-166.
3. Depta JP, Bhatt DL (2010) Atherothrombosis and atrial fibrillation: important and often overlapping clinical syndromes. Thromb Haemost 104: 657-663.
4. Polimeni L, Perri L, Saliola M, Basili S, Violi F (2010) The risk of myocardial infarction in patients with atrial fibrillation: an unresolved issue. Intern Emerg Med 5: 91-94.
5. Mohlenkamp S, Lehmann N, Schmermund A et al (2003) Prognostic value of extensive coronary calcium quantities in symptomatic males-a 5-year follow-up study. Eur Heart J 24: 845-854.
6. Wayhs R, Zelinger A, Raggi P (2002) High coronary artery calcium scores pose an extremely elevated risk for hard events. J Am Coll Cardiol 39: 225-230.
7. Pan NH, Tsao HM, Chang NC, Lee CM, Chen YJ, Chen SA (2009) Dilated left atrium and pulmonary veins in patients with calcified coronary artery: a potential contributor to the genesis of atrial fibrillation. J Cardiovasc Electrophysiol 20: 153-158.
8. Psaty BM, Manolio TA, Kuller LH et al (1997) Incidence of and risk factors for atrial fibrillation in older adults. Circulation 96: 2455-2461.
9. Tsang TS, Barnes ME, Gersh BJ, Bailey KR, Seward JB (2002) Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. Am J Cardiol 90: 1284-1289.
10. Apstein CS, Grossman W (1987) Opposite initial effects of supply and demand ischemia on left ventricular diastolic compliance: the ischemia-diastolic paradox. J Mol Cell Cardiol 19: 119-128.
11. Blackshear JL, Pearce LA, Hart RG, Zabalgoitia M, Labovitz A, Asinger RW, Halperin JL (1999) Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke 30: 834-840.
12. Zabalgoitia M, Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG (1998) Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol 31: 1622-1626.
13. Akar JG, Jeske W, Wilber DJ (2008) Acute onset human atrial fibrillation is associated with local cardiac platelet activation and endothelial dysfunction. J Am Coll Cardiol 51: 1790-1793.
14. Li-Saw-Hee FL, Blann AD, Gurney D, Lip GY (2001) Plasma von Willebrand factor, fibrinogen and soluble P-selectin levels in paroxysmal, persistent and permanent atrial fibrillation. Effects of cardioversion and return of left atrial function. Eur Heart J 22: 1741-1747.
15. Sohara H, Amitani S, Kurose M, Miyahara K (1997) Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmal atrial fibrillation. J Am Coll Cardiol 29: 106-112.
16. Choudhury A, Chung I, Blann AD, Lip GY (2007) Elevated platelet microparticle levels in nonvalvular atrial fibrillation: relationship to p-selectin and antithrombotic therapy. Chest 131: 809-815.
17. Freestone B, Chong AY, Nuttall S, Lip GY (2008) Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res 122: 85-90.
18. Skalidis EI, Zacharis EA, Tsetis DK et al (2007) Endothelial cell function during atrial fibrillation and after restoration of sinus rhythm. Am J Cardiol 99: 1258-1262.
19. Ferro D, Loffredo L, Polimeni L, Fimognari F, Villari P, Pignatelli P, Fuster V, Violi F (2007) Soluble CD40 ligand predicts ischemic stroke and myocardial infarction in patients with nonvalvular atrial fibrillation. Arterioscler Thromb Vasc Biol 27: 2763-2768.
20. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG (1995) Prevalence, age distribution, and gender of patients with atrial fibrillation. analysis and implications. Arch Intern Med 155: 469-473.
21. Tedrow UB, Conen D, Ridker PM, Cook NR, Koplan BA, Manson JE, Buring JE, Albert CM (2010) The long- and short-term impact of elevated body mass index on the risk of new atrial fibrillation the WHS (women's health study). J Am Coll Cardiol 55: 2319-2327.
22. Camm AJ, Kirchhof P, Lip GY et al (2010) Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31: 2369-2429.
23. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ (2001) Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285: 2864-2870.
24. Heeringa J, van der Kuip DA, Hofman A, Kors JA, van Rooij FJ, Lip GY, Witteman JC (2007) Subclinical atherosclerosis and risk of atrial fibrillation: the rotterdam study. Arch Intern Med 167: 382-387.
25. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE (1997) Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 96: 1432-1437.
26. Watanabe H, Tanabe N, Watanabe T, Darbar D, Roden DM, Sasaki S, Aizawa Y (2008) Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation 117: 1255-1260.
27. Perlstein TS, Creager MA (2009) The ankle-brachial index as a biomarker of cardiovascular risk: it's not just about the legs. Circulation 120: 2033-2035.
28. Diehm C, Allenberg JR, Pittrow D et al (2009) Mortality and vascular morbidity in older adults with asymptomatic versus symptomatic peripheral artery disease. Circulation 120: 2053-2061.
29. Fowkes FG, Murray GD, Butcher I et al (2008) Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA 300: 197-208.
30. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137: 263-272.
31. Marini C, De Santis F, Sacco S, Russo T, Olivieri L, Totaro R, Carolei A (2005) Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 36: 1115-1119.
32. Goto S, Bhatt DL, Rother J et al. (2008) Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 156: 855-863, 863. e852.
33. Ruigomez A, Johansson S, Wallander MA, Edvardsson N, Garcia Rodriguez LA (2009) Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. Int J Cardiol 136: 186-192.
34. Disertori M, Latini R, Barlera S et al (2009) Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 360: 1606-1617.
35. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D (2009) Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol 54: 999-1002.
36. Bilato C, Corti MC, Baggio G, Rampazzo D, Cutolo A, Iliceto S, Crepaldi G (2009) Prevalence, functional impact, and mortality of atrial fibrillation in an older Italian population (from the Pro. V. A. study). Am J Cardiol 104: 1092-1097.
37. Naccarelli GV, Varker H, Lin J, Schulman KL (2009) Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104: 1534-1539.
38. Violi F, Criqui M, Longoni A, Castiglioni C (1996) Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A. D. E. P. study. Atherosclerosis 120: 25-35.
39. Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D (1985) The prevalence of peripheral arterial disease in a defined population. Circulation 71: 510-515.
40. Belch J, MacCuish A, Campbell I et al (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337: a1840.
41. Ogawa H, Nakayama M, Morimoto T et al (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300: 2134-2141.
42. Fowkes FG, Price JF, Stewart MC et al (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303: 841-848.
43. Basili S, Raparelli V, Vestri A, Di Tanna GL, Violi F (2010) Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost 103: 766-773.
44. Becker RC, Meade TW, Berger PB et al (2008) The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 776S-814S.
45. Hansen ML, Sorensen R, Clausen MT et al (2010) Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 170: 1433-1441.
46. Schirmer SH, Baumhakel M, Neuberger HR, Hohnloser SH, van Gelder IC, Lip GY, Bohm M (2010) Novel anticoagulants for stroke prevention in atrial fibrillation: current clinical evidence and future developments. J Am Coll Cardiol 56: 2067-2076.